Prosus N.V. (0A28)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 33.88 |
|---|---|
| 52-week range | 33.46 – 63.92 |
| Return, 1 month / 3 months | −5.0% / −10.3% |
| Return, 1 year / 3 years | −44.7% / +29.6% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 34.6% |
| Worst drawdown (1 year) | -46.1% |
| Average daily value traded | 20.96M EUR |
| Dividend yield | 0.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Prosus is a technology investment company based in the Netherlands. It holds a major stake in the Chinese internet group Tencent and owns and backs internet businesses around the world, including online classifieds, food delivery, payments and fintech, and education technology. Its customers are consumers and businesses that use these digital platforms, and its holdings span markets in Europe, Asia, Latin America and Africa. The company is controlled by Naspers, the South African media and internet group.
Prosus N.V. trades under the code 0A28 on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Prosus N.V. (0A28) trades on the London Stock Exchange in UK. It last closed at EUR 33.88 on 27 October 2026.
Its price-based Market X-Ray is 33 out of 100 (a weak price profile), ranking 2,981 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 44.7% and over the last three months it fell 10.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 17 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -16.3% | ||
| From 52-week high | -45.4% | ||
| Momentum | 18 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.3% | ||
| 6-month return | -17.9% | ||
| 12-month return, skipping the last month | -41.8% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 34.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.1% | ||
| Liquidity | 79 · Strong | Trades actively. | |
| Average daily value traded | 20.96M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 25 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.0% |
|---|---|
| 1 month | −5.0% |
| 3 months | −10.3% |
| 6 months | −17.9% |
| 1 year | −44.7% |
| 3 years | +29.6% |
| 5 years | −1.3% |
Signals
| 50-day / 200-day average | 36.08 / 40.49 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.86 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Oct 2025 | EUR 0.2000 |
| 31 Oct 2024 | EUR 0.1000 |
| 2 Nov 2023 | EUR 0.0700 |
| 1 Sep 2022 | EUR 0.1400 |
| 28 Oct 2021 | EUR 0.1400 |
| 22 Oct 2020 | EUR 0.1100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.